On March 13, Zhejiang Regulatory Bureau of China Securities Regulatory Commission (CSRC) disclosed the guidance filing publicity document of Denuo Capital Investment Project - Hangzhou Qiming Medical Devices Co., Ltd. (hereinafter referred to as "Qiming Medical"), which requires guidance on relevant regulations of scientific innovation version.

As a company specializing in providing high-value medical devices for structural heart disease, Qiming Medical is committed to the development and industrialization of minimally invasive treatment for heart valve disease. Qiming Medical focuses on R&D, has two global pioneering products, namely, dry film pre installed interventional valves and interventional self expanding pulmonary artery valves, and has conducted a lot of innovative research and tests, including taking the lead in clinical research in the field of transcatheter valves, implanting and testing Chinese heart valve instruments in Europe, and setting up a heart valve research institute in China.

In 2009, Qiming Medical was officially established with the help of angel investor Zhang Qiming; In 2011, Qiming Medical was the first institutional investor to invest in the first round of A investment, with a valuation of more than 200 million yuan; In 2012, Qiming Medical obtained the B round investment of Denuo Capital, and the valuation has reached 300 million yuan; Subsequently, Denuo Capital introduced institutional investors such as Qiming Venture Capital, Sequoia Capital and Deutsch Capital to introduce Qiming Medical into the rapid development track; Later, Qiming Medical obtained the round C financing of Goldman Sachs Group and the strategic investment of Dehong Capital with a higher valuation; In 2019, Qiming Medical entered the stage of listing guidance.

Venus A-Valve, the first generation of percutaneous interventional prosthetic heart valve system (TAVR) developed by Qiming Medical, was approved for listing by the State Food and Drug Administration (CFDA) in April 2017. It is the first TAVR product approved for listing by CFDA in China, opening a new era of transcatheter valve replacement in China, and becoming a model of high-end innovative medical devices made in China. The transcatheter pulmonary artery valve product Venus P-Valve of Qiming Medical, as the world's first self expanding pulmonary artery valve, has completed 178 implants in 27 centers in nearly 20 countries and regions. The registration research in China has also been completed, and the registration research in the European Union is about to end, that is, it will be approved and listed in China and Europe.